MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid Cancer, Colorectal Adenocarcinoma, and Non Small Cell Lung Cancer)

August 1, 2022

Protocol: EAY131-H

SCHEMA EAY131-H

Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you!

Eligibility:

  1. Patients must have a BRAF V600E or, V600K, V600R or V600D mutation, or another aberration, as identified via the MATCH Master Protocol.
  2. Patients must fulfill all eligibility criteria in the MATCH Master Protocol.
  3. Patients with a diagnosis of metastatic melanoma from a cutaneous, acral, mucosal, or unknown primary site are excluded.
  4. Patients with a diagnosis of papillary thyroid cancer are excluded.
  5. Patients with a diagnosis of non-small cell lung cancer are excluded.
  6. Patients with a diagnosis of cholangiocarcinoma are excluded.
  7. Patients with a diagnosis of low grade serous ovarian cancer are excluded.
  8. Patients must have an ECHO or a nuclear study (MUGA or First Pass) within 4 weeks prior to registration to treatment and must not have a left ventricular ejection fraction (LVEF) < the institutional lower limit of normal (LLN). If the LLN is not defined at a site, the LVEF must be > 50% for the patient to be eligible.
  9. Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment.
  10. Patients with prior exposure to dabrafenib or trametinib on another treatment subprotocol of the MATCH trial are excluded.
  11. Patients who previously received monoclonal antibody therapy (eg. Ipilimumab and others) must have stopped the prior therapy for 8 or more weeks before starting on trametinib and dabrafenib.

Genesys Hurley Cancer Institute

302 Kensington Avenue (Print a Map)
Flint, MI 48503

810-762-8226 | 888-762-8675

Ascension Genesys Hospital
Hurley Medical Center
Michigan Cancer Consortium

Newsletter

Ⓒ 2020 Genesys Hurley Cancer Institute | All Rights Reserved.